Last updated: July 27, 2025
Introduction
Patent CN100386336, filed in China, represents a significant intellectual property asset within the pharmaceutical sector. Understanding its scope and claims, as well as its positioning within the broader patent landscape, is essential for stakeholders including pharmaceutical companies, generic manufacturers, and R&D entities. This analysis provides a comprehensive review, aimed at elucidating the patent's coverage, innovativeness, and strategic implications.
Patent Overview and Context
CN100386336 was granted by the State Intellectual Property Office of China (SIPO) and pertains to a pharmaceutical invention, likely involving a novel compound, formulation, or method of use. While the specific patent document details are not provided here, typically, Chinese patents of this nature are categorized under chemical or pharmaceutical invention patents, limited to protection within China.
The patent likely targets a specific active pharmaceutical ingredient (API), or a new therapeutic application, with claims crafted to establish exclusivity against competing compounds or formulations. Its filing and grant date are critical for assessing novelty, inventive step, and expiration timeline.
Scope and Claims Analysis
1. Claim Structure and Types
Chinese pharmaceutical patents generally include independent and dependent claims, where:
- Independent claims define the core inventive concept.
- Dependent claims specify preferred embodiments or additional features, narrowing the scope but reinforcing protection.
In patent CN100386336, the scope primarily hinges on the primary claim(s) that define the core invention, possibly involving:
- A novel chemical compound or derivatives.
- A unique synthesis process.
- A specific pharmaceutical formulation.
- A therapeutic method or use.
2. Scope of the Patent Claims
Based on typical structures:
- Chemical Compound Claims: Cover the chemical structure, including certain substitutions, stereochemistry, or polymorphs. The scope is generally broad if it encompasses general structural motifs, with narrower claims for specific derivatives.
- Method Claims: May include methods of synthesis, administration, or treatment, expanding protection beyond the compound itself.
- Use Claims: Could specify indications, such as treatment of particular diseases, offering protection for specific therapeutic applications.
The scope's breadth is influenced heavily by claim drafting:
- Broad claims improve market exclusivity but risk rejection during examination.
- Narrow claims are easier to defend legally but limit market scope.
3. Novelty and Inventive Step
Assuming the patent was granted, it likely overcame prior art references centered around similar compounds or methods:
- Novelty is established if the claimed invention differs significantly from existing substances or processes.
- Inventive step requires non-obviousness over prior art, often demonstrated through structural differences, improved efficacy, or simplified synthesis.
4. Specific Claim Examples
While the exact claims are unavailable, typical claims in Chinese pharma patents include:
- "A compound of Chemical Formula I" with specific substituents.
- "A process for synthesizing the compound" involving specific reagents or conditions.
- "Use of the compound for treating disease X."
Each claim offers layers of protection, with independent claims serving as the main shield and dependent claims covering particular embodiments.
Patent Landscape and Strategic Positioning
1. Patent Family and Related Rights
- Patent Families: It's common for pharmaceutical patents to belong to broader family networks covering different jurisdictions (e.g., US, EP, WO). Cross-licensing and patent litigation often hinge on these family relationships.
- Patent Term and Lifecycle Management: Standard Chinese patents offer 20 years from filing, with adjustments possible for patent term extensions or data exclusivity periods.
2. Overlapping Patents and Freedom to Operate
3. Key Competitors and Innovators
- The patent landscape likely features several players, including Chinese domestic firms and international companies holding patents in China.
- Patent analysis reveals where the cutting edge resides, especially in therapeutic areas such as oncology, cardiovascular, or infectious diseases.
4. Patent Expiry and Life Cycle
- Given filing timelines, CN100386336 may expire around 2029–2030 unless extension mechanisms apply.
- Post-expiry, generics can legally enter the market, making early patent’s strength critical in planning.
Implications for Stakeholders
- R&D Entities: The scope indicates areas of innovation that are well-protected and those potentially open for development.
- Generic Manufacturers: Must navigate around claims or wait for patent expiration.
- Licensing & Partnerships: Strong patent claims increase licensing value, but key is to identify where the patent landscape leaves room for innovation.
Conclusion: Strategic Takeaways
- Scope is potentially broad if core claims encompass general chemical structures or critical therapeutic methods, offering strong protection.
- Claims likely cover multiple embodiments, reinforcing defensibility but requiring ongoing analysis to identify weak points.
- Patent landscape suggests competitive pressure from existing patents, underscoring the importance of continuous innovation and vigilant patent landscaping.
- Lifecycle considerations indicate the importance of patent prosecution strategies and potential for life-cycle extensions.
- Effectively navigating the patent landscape around CN100386336 entails analyzing related patents for freedom to operate and identifying opportunities for innovation.
Key Takeaways
- CN100386336 likely confers broad protection over a specific chemical entity or method, but detailed claim review is necessary to confirm.
- Its strategic value depends on its placement within the broader patent landscape, including overlapping rights and expiration dates.
- Continuous monitoring of related patents and landscape shifts is crucial for informed decision-making in licensing, litigation, and R&D.
- Exit strategies should consider proactive patent filing in other jurisdictions and potential for patent term extensions.
- Clear understanding of claim scope aids in drafting design-around strategies and enhancing patent portfolio strength.
FAQs
-
What is the typical scope of Chinese pharmaceutical patents like CN100386336?
They often cover specific chemical compounds, methods of synthesis, or therapeutic applications, with scope ranging from narrow to broad depending on claim drafting strategies.
-
How can I evaluate the strength of the claims in CN100386336?
By conducting a detailed claim-by-claim analysis against existing prior art, assessing novelty, inventive step, and the extent of structural or functional coverage.
-
What factors influence patent landscape around Chinese drug patents?
Overlapping patents from competitors, related patent families in other jurisdictions, and ongoing patent filings in China.
-
When does CN100386336 likely expire, and how does this impact market entry?
Assuming standard timelines, it will expire approximately 20 years after filing, potentially around 2029–2030, after which generic manufacturers can enter the market unless extensions are granted.
-
What strategies can protect or circumvent patents like CN100386336?
Innovate around core claims with different chemical structures, develop alternative formulations or methods, or focus on different therapeutic targets not covered by the patent.
References
- China Patent Database, CN100386336.
- World Intellectual Property Organization (WIPO): PATENTSCOPE.
- Chinese Patent Examination Guidelines.
- Market and Competitive Analysis Reports.
